Stock NEOP NEOPROBE
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases NEOPROBE OTC Bulletin Board

Equities

NEOP

US6405181065

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for NEOPROBE
2023 Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding CI
2023 Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
AQ
Navidea: Q3 Earnings Snapshot
AQ
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
BU
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
AQ
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
BU
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
BU
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
BU
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
AQ
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
BU
NAVIDEA BIOPHARMACEUTICALS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
BU
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
BU
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
BU
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
AQ
NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
BU
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
BU
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAVB Stock
  4. NEOP Stock
  5. News NEOPROBE
  6. Press Releases